Trialbee, a global provider of best-in-class digital patient recruitment and engagement solutions for clinical research, announces the official release of its digital patient engagement solutions. With Trialbee, sponsors, CROs and investigator sites can increase...
Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that the Company has dosed its first patient for its bioequivalence study of Tadalafil (Cialis®) and Finasteride (PROSCAR®) combination tablet for benign prostatic hyperplasia...
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase 2a clinical trial...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced initial clinical data from cohorts in its ongoing Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor...
– 83% overall response rate, with evidence of deepening of response over time – – Median duration of response not reached; 12-month duration of response rate of 76% – – Statistically significant improvements in patient-reported disease...
Email
Text